Press Releases

Arch Biopartners Collaborates With Team at Cincinnati Veterans Affairs Medical Center to Prepare Phase I and II Human Trial Protocol and Application for AB569

TORONTO, ONTARIO–(Marketwired – Oct. 27, 2016) – Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) today announced it has agreed to sponsor Dr. Ralph Panos and his clinical trial team at the Cincinnati Veterans Affairs Medical Center (CVAMC) to prepare a phase I and phase II human trial protocol and an application to conduct investigator initiated trials evaluating the safety and efficacy of AB569.

Read more

Arch Biopartners Announces Issuance of U.S. Patent for Metablok

TORONTO, CANADA–(Marketwired – Oct. 11, 2016) – Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ACH) (OTCBB:FOIFF) announced today the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 9,464,114 titled, “Peptides that Block Leukocyte Recruitment and Methods of Use”.

Read more

Arch Biopartners Engages Catalent to Begin Manufacturing Process for AB569

TORONTO, ONTARIO–(Marketwired – Aug. 10, 2016) – Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) today announced it has engaged Catalent Inhalation, a division of Catalent Pharma Solutions (Catalent), to begin the manufacturing process for its drug AB569 in preparation for the first human trials involving patients with antibiotic resistant lung infections.

Read more

Arch Biopartners Forms Clinical and Medical Advisory Board for AB569

TORONTO, ONTARIO–(Marketwired – July 18, 2016) – Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) today announced the formation of a clinical and medical advisory board for AB569, the Company’s bactericidal drug for treating antibiotic resistant infections in lungs and the urinary tract.

Read more

Arch Biopartners’ AB569 Receives Positive Opinion from EMA COMP for Orphan Designation for Cystic Fibrosis

TORONTO, ONTARIO–(Marketwired – April 26, 2016) – Arch Biopartners Inc. (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF), a portfolio based biotechnology company, today announced the European Medicines Authority (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending AB569 for designation as an orphan medicinal product for the treatment of patients with cystic fibrosis (CF).

Read more

Arch Biopartners Enters Exclusive License Agreement With University of Cincinnati for AB569

TORONTO, ONTARIO–(Marketwired – March 16, 2016) – Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced today it has entered into an exclusive license agreement with the University of Cincinnati (UC) for AB569, a new candidate drug to treat Pseudomonas aeruginosa (P. aeruginosa) respiratory infections.

Recent Developments in the AB569 program

In the last year, Arch management has worked with the lead inventor of AB569, Dr. Daniel Hassett at the University of Cincinnati (UC) College of Medicine, to build the patent portfolio for AB569 and to prepare a clinical development plan to test the safety and efficacy of the drug against P. aeruginosa respiratory infections in cystic fibrosis (CF) patients.

Read more

Arch Scientists Publish Data on the Efficacy and Mechanism of Action of Lead Drug Candidate AB569

TORONTO, ONTARIO–(Marketwired – March 1, 2016) – Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced today that Dr. Daniel Hassett’s team at the University of Cincinnati College of Medicine, and its collaborators, have published details regarding the efficacy of AB569 in killing the pathogenic bacterium Pseudomonas aeruginosa (P. aeruginosa) in the peer-reviewed journal Frontiers in Microbiology. The findings indicate that low doses of acidified nitrite and EDTA (active ingredients of AB569) are highly effective at killing P. aeruginosa. In addition, the article provides information on the drug’s mechanism of action.

Read more